Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10435332 | 0.78 | — | — | |
| SCHEMBL919508 | 0.78 | — | — | |
| SCHEMBL2162067 | 0.78 | — | — | |
| SCHEMBL18991600 | 0.76 | — | — | |
| SCHEMBL28672608 | 0.75 | SMPD1 (0.32) | SMPD1FDPS | |
| SCHEMBL16109725 | 0.72 | SMPD1 (0.32) | SMPD1LMNAFDPSTHRBBLM | |
| SCHEMBL28679464 | 0.72 | SMPD1 (0.32) | SMPD1LMNAFDPSTHRBBLM | |
| SCHEMBL332472 | 0.71 | — | — | |
| SCHEMBL3148932 | 0.71 | — | — | |
| SCHEMBL28729195 | 0.71 | LMNA (0.40) | SMPD1LMNAFDPSBLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103904-A1 | 4-AMINO SUBSTITUTED PYRIDAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2026-05-21 | — | — | WO | disclosed |
| EP-4731627-A1 | IMIDAZO[1,2-A]PYRAZIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF A HELMINTH INFECTION | Merck Patent GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-20250333849-A1 | SOLVENT-BASED COMPOSITIONS AND RELATED METHODS FOR MOLYBDENUM ETCHING | ENTEGRIS INC (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025101944-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-119585261-A | PRMT5 inhibitor, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20250034187-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-30 | — | — | US | disclosed |
| CN-119365459-A | Polycyclic compounds as KRAS G12D inhibitors | 杭州英创医药科技有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2024260951-A1 | IMIDAZO[1,2-A]PYRAZIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF A HELMINTH INFECTION | MERCK PATENT GMBH (DE) | 2024-12-26 | — | — | WO | disclosed |
| US-12152049-B2 | STING agonistic compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-11-26 | — | — | US | disclosed |
| CN-118638153-B | Preparation method of aminopyridine compound | 天津辰欣药物研究有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20130018185-A1 | Synthesis of 2,4-Pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8299242-B2 | Synthesis of 2,4-pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2448950-A1 | SYNTHESIS OF N4- (2, 2-DIMETHYL-4- [ (DIHYDROGEN PHOSPHONOXY]-3-OXO-5-PYRIDO [1, 4]OXAZIN-6-YL)-5-FLUORO-N2- (3, 4, 5,-TRIMETHOXYPHENYL) -2, 4- PYRIMIDINEDIAMINE DISODIUM SALT | Rigel Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
| WO-2011002999-A1 | SYNTHESIS OF N4- (2, 2-DIMETHYL-4- [ (DIHYDROGEN PHOSPHONOXY ] -3-OXO-5-PYRIDO [1, 4] OXAZIN-6-YL)-5-FLUORO-N2- (3, 4, 5,-TRIMETHOXYPHENYL) -2, 4- PYRIMIDINEDIAMINE DISODIUM SALT | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20110003986-A1 | Synthesis of 2,4-Pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| EP-2121029-A2 | PRODRUGS AND METHODS OF MAKING AND USING THE SAME | Neurogesx, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080318905-A1 | Prodrugs and methods of making and using the same | NEUROGESX, INC. | 2008-12-25 | — | — | US | disclosed |
| WO-2008070149-A2 | PRODRUGS AND METHODS OF MAKING AND USING THE SAME | NEUROGESX, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018185-A1 | Synthesis of 2,4-Pyrimidinediamines | DPYD, TYMS, TYMP | SMPD1 3246/4885LMNA 2473/4885FDPS 116/4885 |
| US-20250034187-A1 | STING AGONISTIC COMPOUND | STING1, IRF3, MAVS | SMPD1 425/4885LMNA 2286/4885FDPS 3851/4885 |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | SMPD1 350/4885LMNA 525/4885FDPS 1966/4885 |
| US-20080318905-A1 | Prodrugs and methods of making and using the same | NAPEPLD, CES2, MTAP | SMPD1 41/4885LMNA 2323/4885FDPS 287/4885 |
| US-20110003986-A1 | Synthesis of 2,4-Pyrimidinediamines | DPYD, TYMS, TYMP | SMPD1 3246/4885LMNA 2473/4885FDPS 116/4885 |
| US-12152049-B2 | STING agonistic compound | STING1, IRF3, MAVS | SMPD1 425/4885LMNA 2286/4885FDPS 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.